Magnetic Brain Stimulation for Depression in People With Parkinson's Disease
Tests magnetic brain stimulation against a sham treatment for depression in Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease
Key facts
- Where
- Daegu, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 90 years old?
Source: NCT07569133, who can take part
Where in South Korea
- Kyungpook National University Chilgok HospitalDaegu, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ho-Won Lee
- Trial code
- NCT07569133
- Record updated
- 29 October 2026
- Original description
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in improving depressive symptoms in patients with Parkinson's Disease(PD).Read full original descriptionShow less
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease : A Single-Center, Randomized, Double-Blinded, Sham-Controlled, Parallel-Design, Investigator-Initiated Exploratory Clinical Trial
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in improving depressive symptoms in patients with Parkinson's Disease(PD).
Participants will be randomly assigned to either an active rTMS group or a sham-control group.
The study aims to evaluate the efficacy and feasibility of a neuronavigation-guided bilateral M1 rTMS protocol.
Inclusion: Willing and able to provide written informed consent; Male or female aged 40 to 90 years; Diagnosed with Parkinson's disease with depressive symptoms; Hoehn and Yahr stage 1 to 3; On stable Parkinson's disease medication for at least 3 months prior to screening, with no planned dose increase during the study period; Clinically significant depressive symptoms (BDI-II score ≥14) confirmed by clinician interview, without major psychiatric conditions that may confound their assessment; Able to read and write Korean and capable of independently completing questionnaires.
Exclusion: Patients with artificial hip joint implants; Presence of conductive, ferromagnetic, or magnetically sensitive metal near the head or treatment coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils); Use of drug infusion pumps or hearing aids; Currently enrolled in another clinical trial or used investigational drug/device within 30 days or 5 half-lives prior to consent; History of epilepsy; Parkinson's disease caused by cerebrovascular disease, CNS infection, intoxication, or traumatic brain injury; Diagnosed with Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies etc.); Major psychiatric disorders other than depressive disorders (e.g., bipolar disorder, psychotic disorders) that may interfere with study participation or assessment of depressive symptoms; Cardiac disease, especially patients with pacemakers; Patients with acute illness; Patients taking tricyclic antidepressants, neuroleptics, or other medications that may lower seizure threshold; History of increased intracranial pressure or head trauma; History of schizophrenia, bipolar disorder, or substance abuse; History of or planned deep brain stimulation or stereotactic surgery (pallidotomy, thalamotomy); Any participant deemed ineligible by the investigator, including those with medical conditions that may increase risk or interfere with study evaluation; Clinically significant abnormal laboratory values (AST, ALT, or total bilirubin > 2.5 x ULN); Unable to follow instructions or communicate; Pregnant, breastfeeding, or women of childbearing potential; Febrile patients; Corrected or uncorrected visual acuity less than 0.5; Evidence of external wounds on brain or neck; Prominent psychotic symptoms other than depression (high NPI scores for hallucinations, delusions, mania); Suicidal ideation (BDI-II item 9 score of 2 or 3).